Join to View Full Profile
460 W 10th AveColumbus, OH 43210
Phone+1 614-293-3989
Fax+1 614-293-9789
Dr. Alinari is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2013 - 2016- Ohio State University HospitalResidency, Internal Medicine, 2011 - 2013
University of BolognaPhD, Experimental Therapeutics for Hematologic Malignancies, 2008 - 2011
University of Florence Faculty of MedicineClass of 1998
Certifications & Licensure
OH State Medical License 2011 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
Clinical Trials
- Ibrutinib and Nivolumab in Treating Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Start of enrollment: 2016 Dec 20
- A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma Start of enrollment: 2019 Oct 15
Roles: Principal Investigator
- Tegavivint for Treating Patients with Relapsed or Refractory Large B-Cell Lymphoma Start of enrollment: 2023 Mar 06
Roles: Contact, Sponsor-Investigator, Principal Investigator
Publications & Presentations
PubMed
- TP53 mutations and TET2 deficiency cooperate to drive leukemogenesis and establish an immunosuppressive environment.Pu Zhang, Ethan C Whipp, Sarah J Skuli, Mehdi Gharghabi, Caner Saygin
The Journal of Clinical Investigation. 2025-03-20 - Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies.Elvira Umyarova, Charles Pei, William Pellegrino, Qiuhong Zhao, Nidhi Sharma
Journal of Hematology & Oncology. 2025-03-18 - Targeting the DNA Damage Response through TBL1X in Mantle Cell Lymphoma.Betsy Pray, Ethan James Baiocchi, Sydney Leon, Brian Barta, Shirsha Koirala
Blood Advances. 2025-02-26
Abstracts/Posters
- Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of...Lapo Alinari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Phase I Study of Nivolumab and Lenalidomide in Relapsed/ Refractory B Cell LymphomaLapo Alinari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- PRMT5 Inhibition Drives Therapeutic Vulnerability to BCL-2 Inhibition with Venetoclax and Provides Rationale for Combination Therapy in Mantle Cell LymphomaLapo Alinari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Press Mentions
Recipients of AACR Research Funding & Fellowships 1993–2017September 8th, 2017
Grant Support
- Trispecific CAR-T cells targeting CD19, CD20 and CD22 to treat B-cell malignanciesOHIO STATE UNIVERSITY2023–2028
- Trispecific CAR-T cells targeting CD19, CD20 and CD22 to treat B-cell malignanciesOHIO STATE UNIVERSITY2023–2028
- Targeting c-Myc stability in c-Myc overexpressing large B-cell lymphomaOHIO STATE UNIVERSITY2022–2027
- Targeting c-Myc stability in c-Myc overexpressing large B-cell lymphomaOHIO STATE UNIVERSITY2022–2027
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
